Losartan to prevent hyperenzymemia after endoscopic retrograde cholangiopan-creatography: A randomized clinical trial

Table 3 Serum pancreatic enzyme levels, abdominal pain, and pancreatitis after endoscopic retrograde cholangiopancreatography among 76 participating patients¹n (%)

Pancreatic enzyme level in serum	Losartan group	Placebo group	P value
Amylase (microkat/L), median, (interquartile range)
At baseline	0.44 (0.3)	0.46 (0.4)	0.64
4 h after ERCP	0.75 (2.5)	0.68 (1.0)	0.81
24 h after ERCP	0.62 (2.3)	0.82 (1.0)	0.33
Hyperamylasemia2 24 h after ERCP, number (%)	8 (24)	4 (13)	0.53
Missing data	5 (13)	6 (16)
Lipase (microkat/L), median, (interquartile range)
At baseline	0.53 (0.3)	0.48 (0.5)	0.47
4 h after ERCP	1.02 (5.9)	0.76 (1.4)	0.47
24 h after ERCP	0.77 (1.1)	1.07 (1.5)	0.62
Hyperlipasemia2 24 h after ERCP, number (%)	8 (21)	7 (18)	0.89
Missing data	5 (13)	7 (18)
Hyperenzymemia3 24 h after ERCP, number (%)	9 (24)	7 (18)	0.51
Missing data	4 (11)	3 (8)
Abdominal pain 24 h after ERCP, number (%)	8 (23)	9 (26)	0.93
Missing data	3 (8)	3 (8)
Acute pancreatitis (hyperenzymemia and abdominal pain after 24 h), number (%)	5 (13)	4 (11)	0.57
Missing data	7 (18)	4 (11)

¹In all analyses missing values were included as a separate category; P-values refer to overall differences between groups;

²Defined as 3 times higher than the normal reference value;

³Occurrence of hyperamylasemia or hyperlipasemia. ECRP: Endoscopic retrograde cholangiopancreatography.